作者：王依阳1 ，赵慧1 ，蒋红英1 ，梁宸源1 ，许百灵2 ，方纬3 ，程功1

单位：

1.710068陕西省西安市，陕西省人民医院心血管内二科　2.65211美国哥伦比亚，密苏里哥伦比亚大学核科 学暨工程研究所　3.100037北京市，中国医学科学院阜外医院核医学科

单位（英文）：

1.Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an 710068, China 2.Institute of Nuclear Science and Engineering, University of Missouri-Columbia, Columbia 65211, USA 3.Nuclear Medicine Department, Fuwai Hospital Chinese Academy of Medical Sciences, Beijing 100037, China

关键词：

　冠心病；经皮冠状动脉介入治疗；冠状动脉微血管疾病；葛兰心宁；生长分化因子15；精氨酸酶

关键词（英文）：

Coronary disease; Percutaneous coronary intervention; Coronary microvascular disease; Gelanxinning; Growth differentiation factor 15; Arginase

中图分类号：

R 541.4

DOI：

10.12114/j.issn.1008-5971.2024.00.059

基金项目：

陕西省中医药管理局项目（2021-ZZ-ZY003）；陕西省人民医院科技创新领军人才项目（2022LJ-04）

摘要：

目的　探讨葛兰心宁软胶囊对PCI后合并冠状动脉微血管疾病（CMVD）的冠心病患者生长分化因子 15（GDF-15）、精氨酸酶的影响。方法　选取2021年7月—2022年 7月陕西省人民医院收治的 PCI后合并CMVD的冠心 病患者78例为研究对象，采用随机数字表法将患者分为试验组（ n =38 ）和对照组（n=40）。对照组给予常规治疗，试 验组在对照组的基础上给予葛兰心宁软胶囊，两组患者均连续治疗2个月。比较两组治疗前后GDF-15、精氨酸酶，采 用西雅图心绞痛量表（SAQ）评价患者生活质量，观察治疗期间两组不良反应发生情况。结果　治疗后两组GDF-15、 精氨酸酶分别低于本组治疗前，且试验组GDF-15、精氨酸酶低于对照组（P＜0.05）。治疗后两组SAQ评分分别高于 本组治疗前，且试验组SAQ评分高于对照组（P＜0.05）。两组肠胃不适、恶心呕吐、过敏、出血、肝肾功能异常发生 率比较，差异无统计学意义（P＞0.05）。结论　葛兰心宁软胶囊可降低PCI后合并CMVD的冠心病患者GDF-15、精氨 酸酶，提高患者生活质量，且安全性好。

英文摘要：

Objective To explore the effect of Gelanxinning soft capsule on growth differentiation factor 15 (GDF-15) and arginase in coronary heart disease patients with coronary microcirculation disease (CMVD) after PCI. Methods A total of 78 coronary heart disease patients with CMVD after PCI admitted to Shaanxi Provincial People's Hospital from July 2021 to July 2022 were selected as the study subjects. The patients were divided into experimental group (n=38) and control group (n=40) using a random number table method. The control group was given routine treatment, and experimental group was given Gelanxinning soft capsule on the basis of control group. The treatment time of both groups was 2 months. GDF-15 and arginase were compared between the two groups before and after treatment. Quality of life of patients was evaluated by the Seattle Angina Questionnaire (SAQ) , and the occurrence of adverse reactions during treatment of the two groups was observed. Results After treatment, the GDF-15 and arginase of the two groups were lower than those before treatment respectively, the GDF-15 and arginase in the experimental group were lower than those in the control group (P < 0.05) . After treatment, the SAQ score of the two groups was higher than that before treatment respectively, the SAQ score in the experimental group was higher than that in the control group (P < 0.05) . There was no significant difference in the incidence of gastrointestinal discomfort, nausea and vomiting, allergies, bleeding, and liver and kidney dysfunction between the two groups (P > 0.05) . Conclusion Gelanxinning soft capsule can reduce the GDF-15 and arginase in coronary heart disease patients with CMVD after PCI, improve the quality of life, and has good safety.

参考文献：